舒普深联合莫西沙星治疗慢阻肺合并急性下呼吸道感染的效果及安全性观察

目的 探讨舒普深联合莫西沙星治疗慢阻肺(COPD)合并急性下呼吸道感染的效果及安全性.方法 54例COPD合并急性下呼吸道感染患者随机均分为两组.对照组采用舒普深治疗,观察组在对照组基础上采用莫西沙星治疗.比较两组的治疗效果、免疫功能及不良反应.结果 观察组的总有效率为96.30％,显著高于对照组的59.26％ (P ...

Observation on the Effect and Safety of Sulperazon Combined with Moxifloxacin in the Treatment of COPD Complicatedwith Acute Lower Respiratory Tract Infection

Objective To explore the effect and safety of sulperazon combined with moxifloxacin in the treatment of COPD complicated with acute lower respiratory tract infection.Methods 54 patients with COPD complicated with acute lower respiratory tract infection were randomly and equally divided into two groups.The control group was treated with sulperazon,and the observation group was treated with moxifloxacin on the basis of control group.The therapeutic effect,immune function and adverse reactions were compared between two groups.Results The total effective rate of observation group was 96.30%,significantly higher than 59.26%of control group(P<0.05).After 14 days of treatment,the levels of CD3⁺and CD4⁺/CD8⁺of observation group were significantly higher than those of control group,and the level of CD8⁺was significantly lower than that of control group(P<0.05).No significant difference was found in the incidence of adverse reactions between two groups(P>0.05).Conclusions Sulperazon combined with moxifloxacin in the treatment of COPD complicated with acute lower respiratory tract infection has significant effect and high safety,and can effectively improve patients'immune function.